Key result
Modulation of the glycoprotein VI (GPVI) platelet receptor represents a novel antiplatelet strategy for thrombosis, with recent development focusing on small molecule modulators.
Why the study?
Despite existing anticoagulants and antiplatelet agents, thrombosis-related mortality remains high, prompting investigation into modulating the glycoprotein VI platelet receptor as a novel antiplatelet strategy.
Design
Review
Authors
Loading...
GPVI modulation may offer a new antiplatelet approach in thrombosis; leaves open the need for clinical validation of small-molecule candidates.
Modulation of the glycoprotein VI (GPVI) platelet receptor represents a promising novel antiplatelet strategy for the treatment of thrombosis.
Foster et al. (2020) conducted a review in Thrombosis. Glycoprotein VI (GPVI) modulators was evaluated. Modulation of the glycoprotein VI (GPVI) platelet receptor represents a novel antiplatelet strategy for thrombosis, with recent development focusing on small molecule modulators.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: